Evidence map›Paper›PMID 33139339›Full record

ArticleCancer discovery2020

An Expanded Tool Kit for Modeling the Oncogenic Functions of KRAS.

Kaja Kostyrko, E Alejandro Sweet-Cordero

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

  • Comment on
    An2020
5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kaja KostyrkoDepartment of Pediatrics, University of California, San Francisco, San Francisco, California.
E Alejandro Sweet-CorderoDepartment of Pediatrics, University of California, San Francisco, San Francisco, California. alejandro.sweet-cordero@ucsf.edu.ORCID https://orcid.org/0000-0002-9787-9351
University of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zafra and colleagues developed new mouse models to study the role of specific KRAS mutations in pancreatic, lung, and colon cancer pathogenesis. Their studies clearly describe the distinct ability of these mutations to drive pathogenesis in a tissue-specific fashion.

Indexed as

OncogenesProto-Oncogene Proteins p21(ras)AnimalsCarcinogenesisGenes, rasMiceMutationPhenotypeProto-Oncogene Proteins p21(ras)

Identifiers

PMID33139339
OpenAlexW3096911817

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.